Active — Not RecruitingNot Applicable

Quantifying Steatosis in Liver Transplant Donors

Hong Kong100 participantsStarted 2015-10

Plain-language summary

Non-alcoholic fatty liver disease is the most common chronic liver disease in Hong Kong. Its presence among donors of living donor liver transplants could affect the outcomes of recipients of liver transplantation. By using controlled attenuation parameter (CAP) measurements, the investigators aim to investigate the association of CAP measurements and severity of fatty liver among liver donors in the recipient outcomes of living donor liver transplantation.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18-60 LDLT donor who has completed donor workup * Consents to study entry Exclusion Criteria: * Concomitant liver disease, including chronic hepatitis B and C infection, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, Wilson disease, and increased alcohol intake (30g per week for male, 20g per week for female).

What they're measuring

Recipient allograft short-term outcomes

Timeframe: Up to 30 days

Recipient allograft long-term outcomes

Timeframe: Up to 1 year

Trial details

NCT IDNCT02579408

SponsorThe University of Hong Kong

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-05

View on ClinicalTrials.gov More Non-alcoholic Fatty Liver Disease trials